<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-358-02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LAMISIL 250 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TERBINAFINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS PHARMA PRODUKTIONS GMBH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA PRODUKTIONS GMBH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        D01BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>- What Lamisil is</strong></p><p>Lamisil tablets contain the active substance terbinafine hydrochloride which belongs to the group of medicines called antifungal agents.</p><p><em>&nbsp;</em></p><p><strong>- What Lamisil is used for</strong></p><p>Lamisil tablets are used to treat fungal infections of the fingernails and toenails, tinea (ringworm) infections of the scalp and hair, groin and other body areas and the feet (athlete&rsquo;s foot), as well as yeast infections of the skin.</p><p>When taken by mouth, terbinafine reaches the site of infection in concentrations strong enough to kill the fungus or stop it growing.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lamisil tablets will only be prescribed for you by a doctor. Follow all your doctor&rsquo;s instructions carefully, even if they differ from the general information contained in this leaflet.</p><p><strong>a. Do not take Lamisil:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are allergic</strong> (hypersensitive) to Lamisil or any of the other ingredients of Lamisil listed at the end of this leaflet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have or had any liver problems.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have any kidney problems.</strong></p><p>If any of these apply to you, <strong>tell your doctor without taking</strong> Lamisil.</p><p>If you think you may be allergic, ask your doctor for advice.</p><p>&nbsp;</p><p><strong>b. Take special care with Lamisil:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you take</strong> <strong>other medicines (see &ldquo;Taking other medicines&rdquo;)</strong>.</p><p>If any of the following apply to you before or during treatment with Lamisil, <strong>tell your doctor</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or experience symptoms such as unexplained persistent nausea, vomiting, stomach pain, loss of appetite, unusual tiredness, if your skin or the whites of your eyes look yellow, that your urine is unusually dark or your bowel motions are unusually light in color (signs of liver problems). Before and periodically after starting treatment with Lamisil your doctor might take blood tests to monitor your liver function. In case of abnormal test results he or she may ask you to stop taking Lamisil.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience any skin problem such as rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible signs of serious skin reactions), rash due to high level of a specific type of white blood cells (eosinophilia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or experience thickened patches of red/silver skin (psoriasis) or facial rash, joint pain, muscle disorder, fever (cutaneous and systemic lupus erythematosus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience weakness, unusual bleeding, bruising or frequent infections (signs of blood disorders).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking or have recently taken any other medicine, refer to &ldquo;Taking other medicines&rdquo; in this leaflet.</p><p>&nbsp;</p><p><strong>c. Taking other medicines</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including herbal medicines, oral contraceptives (birth control pills) and non-prescription medicines. Some other medicines may interact with Lamisil. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat stomach ulcers (e.g. cimetidine),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat fungal infections (e.g. fluconazole, ketoconazole),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat infectious diseases called antibiotics (e.g. rifampicin),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat mood disorders (some antidepressants such as tricyclic antidepressants, selective serotonine reuptake inhibitors including class 1A, 1B and 1C, monoamine oxidase inhibitors Type B, desipramine),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat high blood pressure (some beta-blockers such as metoprolol),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat irregular heart rhythm (some antiarrhythmics such as propafenone, amiodarone),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat cough (e.g. dextrometorphan),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; caffeine,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin, a medicine used to control your body&rsquo;s immune system (e.g. in order to prevent rejection of transplanted organs).</p><p>Be sure to tell your doctor about these, or any other medicines you take.</p><p>&nbsp;</p><p><strong>d. Taking Lamisil with food and drink</strong></p><p>Lamisil tablets can be taken on an empty stomach or after a meal.</p><p>&nbsp;</p><p><strong>Older people (aged 65 years and above)</strong></p><p>You can take Lamisil tablets if you are aged 65 years and over at the same dose as younger adults.</p><p>&nbsp;</p><p><strong>Children and adolescents (aged 2 years to 17 years)</strong></p><p>Lamisil tablets are not recommended</p><p>&nbsp;</p><p><strong>e. Pregnancy and breast-feeding</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Your doctor will discuss with you the potential risk of taking Lamisil during pregnancy.</p><p>If you are pregnant or think you may be pregnant, tell your doctor. You should not take Lamisil during pregnancy unless specifically advised to do so by your doctor.</p><p>You should not breast-feed while taking Lamisil tablets because your baby would be exposed to terbinafine through your breast milk. This might harm your baby.</p><p>&nbsp;</p><p>Ask your doctor, health care provider or pharmacist for advice before taking any medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow your doctor&rsquo;s instructions carefully. Do not exceed the recommended dosage. If you have the impression that the effect of Lamisil is too strong or too weak, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>How much to take and how often</p><p><u>Adults</u></p><p>The usual dose is one 250 mg tablet daily.</p><p><u>Children</u></p><p>Lamisil tablets are not recommended for use in children</p><p>When to take Lamisil</p><p>Taking Lamisil at the same time each day will help you remember when to take your medicine. Lamisil tablets can be taken on an empty stomach or after a meal.</p><p>&nbsp;</p><p>How to take Lamisil</p><p>You should take Lamisil tablets orally with water.</p><p>&nbsp;</p><p>How long to take Lamisil</p><p>This will depend on the type of infection you have, how severe it is, and what part of your body is affected. Your doctor will tell you exactly for how long you will need to take the tablets.</p><p>The normal duration of treatment is as follows:</p><p>For tinea (ringworm) infections of the feet (athlete&#39;s foot), Lamisil tablets are usually taken for 2 to 6 weeks.</p><p>For tinea (ringworm) and yeast infections of the groin and other body areas, Lamisil tablets are usually taken for 2 to 4 weeks.</p><p>It is important to take your tablet(s) every day and to continue to take it/them for as long as your doctor tells you to. This will ensure that the infection is completely cured and lessen the chance of its return after you stop taking the tablets.</p><p><em><u>Hair and scalp infections</u></em></p><p>The normal duration of treatment for tinea (ringworm) infections of the scalp and hair is 4 weeks.</p><p><em><u>Nail infections</u></em></p><p>Fungal nail infections usually take longer to cure than fungal skin infections. For most nail infections, Lamisil tablets have to be taken for 6 to 12 weeks.</p><p><strong><em><u>Fingernail infection</u></em></strong></p><p>Treatment duration: 6 weeks is sufficient in most cases.</p><p><strong><em><u>Toenail infection</u></em></strong></p><p>Treatment duration: 12 weeks is sufficient in most cases.</p><p>Some patients with poor nail growth may need longer treatment. Your doctor will discuss it with you.</p><p>&nbsp;</p><p>a. If you take more Lamisil than you should</p><p>If you have accidentally taken too many tablets, <strong>contact a doctor or hospital for advise straight away</strong>. You may require medical attention. The same applies if someone else has accidentally taken your medicine. Symptoms caused by an overdose of Lamisil tablets include headache, nausea, stomach pain and dizziness.</p><p>&nbsp;</p><p>b. If you forget to take Lamisil</p><p>Take your tablet(s) as soon as you remember, unless it is less than 4 hours before your next dose is due. In this case, wait and take your next dose at the usual time. Do not take a double dose to make up for the one that you missed.</p><p>&nbsp;</p><p>What else should you be aware of while taking Lamisil?</p><p>There are other measures that you can take to help clear up your infection and make sure it does not return. For example, keep the infected areas dry and cool and change clothing that is in direct contact with the infected area(s) daily.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with all medicines, some patients taking Lamisil tablets may experience some unwanted effects (side effects), although not everybody gets them.</p><p>Some side effects could be serious:</p><p>Rarely Lamisil tablets can cause liver problems, in very rare cases the liver problems can be serious. Serious side effects also include a decrease in certain types of blood cells, lupus (an autoimmune disease), serious skin reactions, severe allergic reactions, inflammation of blood vessels, inflammation of the pancreas or muscle necrosis.<strong> </strong></p><p><strong>Tell your doctor immediately</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience symptoms such as unexplained persistent nausea, stomach problems, loss of appetite or unusual tiredness or weakness or if you notice that your skin or the whites of your eyes look yellow, that your urine is unusually dark or your bowel motions are unusually light in color (possible signs of liver problems).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you develop fever, shivering, a sore throat or mouth ulcers due to infections and weakness or if you get infections more frequently or if you experience unusual bleeding or bruising (possible signs of diseases that affect the amounts of certain types of blood cells).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience difficulty in breathing, dizziness, swelling mainly of the face and throat, flushing, crampy abdominal pain and loss of consciousness or if you experience symptoms such as joint pain, stiffness, rash, fever or swollen/enlarged lymph nodes (possible signs of severe allergic reactions).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience symptoms such as rash, fever, itching, tiredness or If you notice appearance of purplish-red spots under the skin surface (possible signs of blood vessel inflammation).&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you develop any skin problems such as rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience severe upper stomach pain with radiation to the back (possible signs of pancreas inflammation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience unexplained muscle weakness and pain or dark (red-brown) urine (possible signs of muscle necrosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you notice abnormal pale skin, mucosal lining or nail beds, unusual tiredness or weakness or breathlessness on exertion (possible signs of a disease that affects the level of red blood cells)&rdquo;.</p><p><strong>&nbsp;</strong></p><p><strong>The following side effects have been reported with Lamisil:</strong></p><p><strong>Some side effects are very common (<em>likely to</em> <em>affect more than 1 in every 10 patients</em>):</strong></p><p>Headache, nausea, mild abdominal pain, stomach discomfort after meal (heartburn), diarrhea, swelling or bloating (a feeling of fullness) of the abdomen, loss of appetite, skin rashes (itchy), joint pain and muscle pain.</p><p><strong>Some side effects are common (<em>likely to affect 1 to 10 in every 100 patients</em>):</strong></p><p>Mood disorder (depression), disturbance or loss of sense of taste, dizziness, eye disorder and tiredness.</p><p><strong>Some side effects are uncommon (<em>likely to affect 1 to 10 in every 1,000 patients</em>):</strong></p><p>If you notice abnormal pale skin, mucosal lining or nail beds, unusual tiredness or weakness or breathlessness on exertion (possible signs of a disease that affects the level of red blood cells), anxiety, tingling or numbness and decreased skin sensitivity, increased sensitivity of the skin to sun, noises (e.g. hissing) in ears, fever and weight loss.</p><p><strong>Some side effects are rare (<em>likely to affect 1 to 10 in every 10,000 patients</em>):</strong></p><p>Yellow eyes or skin (liver problems) and abnormal liver function test results.</p><p><strong>Some side effects are very rare (<em>likely to affect less than 1 in every 10,000 patients</em>):</strong></p><p>Decrease in certain types of blood cells, lupus (an autoimmune disease), serious skin reactions, allergic reactions, psoriasis-like skin eruptions (rash with silver coloured appearance), worsening of psoriasis, skin rash with flaking or peeling and hair loss.</p><p><strong>&nbsp;</strong></p><p><strong>The following side effects have also been reported: </strong></p><p>Severe allergic reactions or infections, inflammation of blood vessels, smell disorders including permanent loss of smell, reduced ability to smell, blurred vision, decreased sharpness of vision, inflammation of the pancreas, skin rash due to high level of a specific type of white blood cells, muscle necrosis, flu-like symptoms (e.g. tiredness, chills, sore throat, joint or muscles aching),&nbsp; and increase in blood of a muscle enzyme (creatine phosphokinase).</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p>If you notice any other side effects not mentioned in this leaflet, inform your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>&nbsp; &nbsp; Store your tablets protected from light, in the original pack.</li><li>&nbsp; &nbsp; Do not use after the expiry date shown on the box. The expiry date refers to the last day of that month.</li><li>&nbsp; &nbsp; Do not store above 25<em> </em>&ordm;C.</li><li>&nbsp; &nbsp;&nbsp;Keep out of the reach and sight of children.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>250 mg tablets</u></strong></p><p>- The <strong><em>active substance </em></strong>of Lamisil is terbinafine hydrochloride.</p><p>-The <strong><em>other ingredients</em> </strong>are magnesium stearate; silica colloidal anhydrous; hydroxypropylmethyl cellulose; microcrystalline cellulose; sodium carboxymethyl starch.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lamisil is supplied as scored tablets.
•	250 mg tablets (scored): Each tablet contains 250 mg terbinafine as the hydrochloride.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by Novartis Pharmaceutical Company in 12/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هو لاميزيل</strong></p><p>تحتوي أقراص لاميزيل على المادة الفعالة تيربينافين هيدروكلوريد التي تنتمي إلى مجموعة من الأدوية تُسمَّى المواد المضادة للفطريات.</p><p><strong>&nbsp;</strong></p><p><strong>ما هي استعمالات لاميزيل</strong></p><p>تُستعمَل أقراص لاميزيل لعلاج العدوى الفطرية في أظافر اليدين وأظافر القدمين، وعدوى التينيا (الثعلبة أو القوباء الحلقية) في فروة الرأس والشعر، وثنية الفخذ، ومناطق أخرى من الجسم والقدمين (قدم الرياضي أو سعفة القدمين)، وكذلك العدوى بالخمائر في الجلد.</p><p>عند تناوله بالفم، يصل تيربينافين إلى موضع العدوى بتركيزات ذات قوة كافية لقتل الفطريات أو وقف نموها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لن توصف لك أقراص لاميزيل إلا بواسطة طبيب. التزم بجميع تعليمات طبيبك بكل دقة، حتى إذا كانت مختلفة عن المعلومات العامة المذكورة في هذه النشرة.</p><p>&nbsp;</p><p><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال </strong><strong>لاميزيل:</strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت لديك أرجية</strong> (حساسية مفرطة) تجاه لاميزيل أو أي من المكونات الأخرى في لاميزيل المذكورة في نهاية هذه النشرة.</p><p><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كانت لديك حالياً أو في وقت سابق أي مشاكل في الكبد.</strong></p><p><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كانت لديك أي مشاكل في الكلى.</strong></p><p>إذا انطبق عليك أي من هذه الأمور، <strong>أخبر طبيبك مع الامتناع عن استعمال لاميزيل.</strong></p><p>إذا ظننت أن لديك أرجية (حساسية مفرطة) استشر طبيبك.</p><p>&nbsp;</p><p><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال</strong><strong> </strong><strong>لاميزيل:</strong></p><p><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا استعملت أدوية أخرى (انظر &quot;استعمال أدوية أخرى&quot;).</strong></p><p>إذا انطبق عليك أي من الأمور التالية قبل أو أثناء علاجك بواسطة لاميزيل، <strong>أخبر طبيبك</strong>.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك أو حدثت لديك أعراض مثل غثيان مستمر وغير معروف السبب، قيء، ألم في المعدة، فقدان الشهية، تعب غير معتاد، إذا تحول لون جلدك أو الجزء الأبيض من عينيك إلى اللون الأصفر، أو إذا أصبح لون البول داكناً بشكل غير معتاد، أو إذا أصبح لون البراز فاتحاً بشكل غير معتاد (علامات تدل على وجود مشاكل في الكبد). ربما يطلب منك طبيبك إجراء اختبارات للدم قبل البدء في إعطائك لاميزيل وبصفة دورية بعد ذلك لمراقبة وظائف كبدك. في حالة اختلال نتائج الاختبارات ربما يطلب منك طبيبك أن توقف استعمال لاميزيل.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت لديك أي مشاكل في الجلد، مثل حدوث طفح، احمرار الجلد، بثور في الشفتين، أو العينين، أو الفم، تقشر الجلد، حمى (علامات قد تدل على تفاعلات جلدية خطيرة)، طفح ناتج عن ارتفاع مستوى نوع معيَّن من خلايا الدم البيضاء (كثرة الخلايا الحمضية).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك أو حدثت لديك رُقع سميكة في الجلد ذات لون أحمر/ فضي (صدفية) أو طفح في الوجه، ألم في المفاصل، خلل في العضلات، حمى (مرض الذئبة الحمراء الجلدية والجهازية).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدث لديك ضعف، أو نزف غير معتاد، أو كدمة، أو عدوى متكررة (علامات تدل على اضطرابات في الدم).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستعمل حالياً أو استعملت منذ فترة قصيرة أي دواء آخر، انظر تحت عنوان &quot;استعمال أدوية أخرى&quot; في هذه النشرة.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>ج</strong><strong>. </strong><strong>التداخلات الدوائية من أخذ لاميزيل مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تستعمل حالياً أو إذا كنت قد استعملت منذ فترة قصيرة أي أدوية أخرى، بما في ذلك الأعشاب الطبية، وأقراص منع الحمل، والأدوية التي تُصرَف بدون تذكرة طبية. إن بعض الأدوية الأخرى قد يتداخل مفعولها مع مفعول لاميزيل. هذه تشمل:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستعمَل لعلاج قروح المعدة (مثل سيميتيدين)،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستعمَل لعلاج العدوى الفطرية (مثل فلوكونازول، كيتوكونازول)،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستعمَل لعلاج الأمراض المعدية وتُسمى المضادات الحيوية (مثل ريفامبيسين)،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستعمَل لعلاج اضطرابات المزاج (بعض مضادات الاكتئاب مثل مضادات الاكتئاب ثلاثية الحلقات، المثبطات الانتقائية لإعادة التقاط السيروتونين وتشمل الفئة 1A و 1B و 1C، مثبطات مونوأمين أوكسيديز النوع B، ديسيبرامين)،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستعمَل لعلاج ضغط الدم المرتفع (بعض حاصرات البيتا مثل ميتوبرولول)،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستعمَل لعلاج عدم انتظام ضربات القلب (بعض مضادات اضطراب النظم القلبي مثل بروبافينون، أميودارون)،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تُستعمَل لعلاج السعال (مثل دكستروميثورفان)،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكافيين،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين، وهو دواء يُستعمَل للسيطرة على الجهاز المناعي في جسمك (مثلاً لمنع الجسم من رفض الأعضاء المزروعة).</p><p>احرص على إبلاغ طبيبك بشأن هذه الأدوية أو أي أدوية أخرى تستعملها.</p><p><strong>&nbsp;</strong></p><p><strong>د. تناول لاميزيل &nbsp;مع الطعام والشراب</strong></p><p>يمكن تناول أقراص لاميزيل على معدة خاوية أو بعد الأكل.</p><p><strong>&nbsp;</strong></p><p><strong>المسنون (65 سنة من العمر فأكثر)</strong></p><p>يمكنك أن تستعمل أقراص لاميزيل إذا كنت تبلغ من العمر 65 سنة فأكثر بنفس الجرعة التي توصف للبالغين الأصغر سناً.</p><p>&nbsp;</p><p><strong>الأطفال والمراهقون (ابتداء من سنتين إلى 17 سنة من العمر)</strong></p><p>لا يوصَى باستعمال أقراص لاميزيل في الأطفال.</p><p>&nbsp;</p><p><strong>هـ. الحمل والرضاعة </strong></p><p>استشيري طبيبك أو الصيدلي قبل استعمال أي دواء.</p><p>سيناقش معك طبيبك المخاطر الممكنة التي قد تترتب على إعطائك لاميزيل أثناء الحمل.</p><p>إذا كنت حاملاً، أو إذا اشتبهت في أنك حامل، أخبري طبيبك. لا ينبغي أن تستعملي لاميزيل أثناء الحمل ما لم يوصيك طبيبك بشكل محدد بأن تفعلي ذلك.</p><p>يجب أن تمتنعي عن الإرضاع أثناء استعمال لاميزيل أقراص، وذلك لأن طفلك سيتعرَّض لتيربينافين من خلال لبن ثديك، وهذا قد يسبب الأذى لطفلك.</p><p>&nbsp;</p><p>اطلبي النصيحة من طبيبكِ، مقدم الرعاية الصحية أو الصيدلي قبل أخذ أي دواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>التزم بتعليمات طبيبك بكل دقة. لا تتجاوز الجرعة الموصَى بها. إذا شعرت بأن تأثير لاميزيل أقوى أو أضعف مما ينبغي، تحدث مع طبيبك أو مع الصيدلي.</p><p>&nbsp;</p><p><strong>ما هي الكمية التي ينبغي أن تأخذها وما هو معدل تكرارها</strong></p><p><strong><em><u>البالغون</u></em></strong></p><p>الجرعة المعتادة هي قرص واحد 250 مجم يومياً.</p><p><strong><em><u>الأطفال</u></em></strong></p><p>لا يوصَى باستعمال أقراص لاميزيل في الأطفال.</p><p>&nbsp;</p><p><strong>متى ينبغي أن تأخذ لاميزيل</strong></p><p>إن أخذ لاميزيل في نفس الموعد كل يوم سيساعدك على تذكر موعد تناول دوائك. يمكن تناول أقراص لاميزيل على معدة خاوية أو بعد الأكل.</p><p><strong>&nbsp;</strong></p><p><strong>كيف تأخذ لاميزيل</strong></p><p>يتم تناول أقراص لاميزيل عن طريق الفم مع الماء.</p><p>&nbsp;</p><p><strong>ما هي مدة استعمال لاميزيل</strong></p><p>هذا يعتمد على نوع العدوى لديك، ومدى شدتها، ومكان الإصابة في جسمك. سوف يخبرك طبيبك بالضبط عن المدة التي ستحتاج أن تستعمل خلالها الأقراص.</p><p>المدة المعتادة للعلاج هي كما يلي:</p><p>في حالات عدوى التينيا (القوباء الحلقية) في القدمين (قدم الرياضي أو سعفة القدم)، تؤخذ أقراص لاميزيل عادةً لمدة 2 إلى 6 أسابيع.</p><p>في حالات عدوى التينيا (القوباء الحلقية) والعدوى بالخمائر في ثنية الفخذ والأماكن الأخرى من الجسم، تؤخذ أقراص لاميزيل عادةً لمدة 2 إلى 4 أسابيع.</p><p>من المهم أن تأخذ أقراصك كل يوم وأن تستمر في استعمالها طوال المدة التي وصفها لك الطبيب. هذا سيضمن الشفاء التام للعدوى، وسيقلل من احتمال انتكاسها بعد أن توقف استعمال الأقراص.</p><p><strong><em><u>عدوى الشعر وفروة الرأس</u></em></strong></p><p>المدة المعتادة لعلاج عدوى التينيا (القوباء الحلقية) في فروة الرأس والشعر هي 4 أسابيع.</p><p><strong><em><u>عدوى الأظافر</u></em></strong></p><p>تستغرق عادةً العدوى الفطرية في الأظافر مدة أطول للشفاء عن العدوى الفطرية في الجلد. في معظم حالات العدوى في الأظافر، يلزم استعمال أقراص لاميزيل لمدة 6 إلى 12 أسبوعاً.</p><p><strong><em><u>عدوى أظافر اليدين</u></em></strong></p><p>مدة العلاج: 6 أسابيع تكون كافية في معظم الحالات.</p><p><strong><em><u>عدوى أظافر القدمين</u></em></strong></p><p>مدة العلاج: 12 أسبوعاً تكون كافية في معظم الحالات.</p><p>بعض المرضى الذين لديهم ضعف في نمو الظفر قد يحتاجون إلى علاج أطول. سوف يناقش معك طبيبك هذا الأمر.</p><p>&nbsp;</p><p><strong>أ. </strong><strong>الجرعة الزائدة من </strong><strong>لاميزيل</strong></p><p>إذا أخذت على سبيل الخطأ عدداً من الأقراص أكثر مما ينبغي، <strong>اتصل فوراً بطبيبك أو بالمستشفى طلباً للاستشارة</strong>. فإنك قد تحتاج إلى رعاية طبية. هذا ينطبق أيضاً في حالة ما إذا أخذ شخص آخر دواءك على سبيل الخطأ. الأعراض الناتجة عن الجرعة المفرطة من أقراص لاميزيل تشمل الصداع، والغثيان، والألم البطني، والدوخة.</p><p>&nbsp;</p><p><strong>ب. </strong><strong>نسيان تناول جرعة من</strong><strong> لاميزيل</strong></p><p>خذ أقراصك بمجرد أن تتذكرها، ما لم يكن متبقياً أقل من 4 ساعات قبل أن يحين موعد جرعتك التالية. في هذه الحالة،&nbsp; انتظر وخذ جرعتك التالية في موعدها المعتاد. لا تأخذ جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p>&nbsp;</p><p><strong>ما الذي يجب أن تتنبه له أيضاً أثناء استعمال </strong><strong>لاميزيل؟</strong></p><p>هناك إجراءات أخرى يمكنك اتخاذها لكي تساعد على التخلص من العدوى وتضمن عدم انتكاسها. على سبيل المثال، حافظ على جفاف وبرودة المناطق المصابة، واحرص يومياً على تغيير الملابس الملامسة للمناطق المصابة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، فإن بعض المرضى الذين يستعملون أقراص لاميزيل قد يتعرضون لحدوث بعض الآثار غير المرغوبة (آثار جانبية)، غير أنها لا تحدث لجميع الأشخاص.<strong>&nbsp;</strong></p><p><strong>بعض الآثار الجانبية قد تكون خطيرة:</strong></p><p>قد تؤدي أقراص لاميزيل بصفة نادرة إلى حدوث مشاكل في الكبد؛ في حالات نادرة جداً قد تكون المشاكل في الكبد خطيرة. الآثار الجانبية الخطيرة قد تشمل أيضاً نقص أنواع معيَّنة من خلايا الدم، مرض الذئبة (أحد أمراض المناعة الذاتية)، تفاعلات جلدية خطيرة، تفاعلات حساسية خطيرة، التهاب الأوعية الدموية، التهاب البنكرياس، أو حدوث نخر في العضلات.</p><p><strong>أخبر طبيبك فوراً:</strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت لديك أعراض مثل إسهال مستمر غير معروف السبب، مشاكل في المعدة، فقدان الشهية، أو تعب أو ضعف غير معتاد، أو إذا لاحظت تحول لون جلدك أو الجزء الأبيض من عينيك إلى اللون الأصفر، أو إذا أصبح لون البول داكناً بشكل غير معتاد، أو إذا أصبح لون البراز فاتحاً بشكل غير معتاد (علامات تدل على وجود مشاكل في الكبد).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت لديك حمى، رعشة، التهاب الحلق، أو قروح في الفم بسبب عدوى، وضعف، أو إذا حدثت لديك عدوى بشكل أكثر تكراراً أو إذا حدث لديك نزف أو كدمات بشكل غير معتاد (علامات قد تُشير إلى أمراض تؤثر على كمية أنواع معيَّنة من خلايا الدم).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت لديك صعوبة في التنفس، دوخة، تورم أساساً في الوجه والحلق، توهج، ألم في البطن من النوع التقلصي، فقدان الوعي، أو إذا حدثت لديك أعراض مثل ألم المفاصل، تيبس، طفح، حمى، أو تورم/ تضخم العقد الليمفاوية (علامات قد تدل على تفاعلات حساسية شديدة).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت لديك أعراض مثل الطفح، الحمى، الحكة، التعب أو إذا لاحظت ظهور بقع حمراء تميل إلى اللون الأرجواني تحت سطح الجلد (علامات قد تدل على التهاب الأوعية الدموية).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت لديك مشاكل في الجلد مثل الطفح، احمرار الجلد، بثور في الشفتين، أو العينين، أو الفم، تقشر الجلد، حمى.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدث لديك ألم شديد في أعلى البطن ينتشر نحو الظهر (علامات قد تدل على التهاب البنكرياس).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدث لديك ضعف عضلي وألم عضلي غير معروف السبب أو تحول البول إلى اللون الداكن (أحمر بني) (علامات قد تدل على النخر العضلي).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت حدوث شحوب غير معتاد في الجلد، أو في الأغشية المخاطية، أو في أرضية الظفر، تعب غير معتاد أو ضعف أو انقطاع التنفس عند عمل مجهود (علامات قد تدل على مرض يُصيب مستوى خلايا الدم الحمراء).</p><p>&nbsp;</p><p><strong>تم الإبلاغ عن الآثار الجانبية التالية مع لاميزيل:</strong></p><p><strong>بعض الآثار الجانبية شائعة جداً <em>(تُصيب على الأرجح أكثر من 1 من كل 10 مرضى)</em>:</strong></p><p>صداع، غثيان، ألم بطني طفيف، عناء في المعدة بعد الأكل (حُرقة الفؤاد)، إسهال، انتفاخ أو وجود غازات في البطن (الشعور بالامتلاء)، فقدان الشهية، طفح جلدي (حكة)، ألم في المفاصل وألم في العضلات.</p><p>&nbsp;</p><p><strong>بعض الآثار الجانبية شائعة <em>(تُصيب على الأرجح 1 إلى 10 من كل 100 مريض)</em>:</strong></p><p>خلل في المزاج (اكتئاب)، خلل أو فقدان حاسة التذوق، دوخة، خلل في العينين، وتعب.</p><p><strong>&nbsp;</strong></p><p><strong>بعض الآثار الجانبية غير شائعة <em>(تُصيب على الأرجح 1 إلى 10 من كل 1000 مريض)</em>:</strong></p><p>إذا لاحظت حدوث شحوب غير معتاد في الجلد، أو في الأغشية المخاطية، أو في أرضية الظفر، تعب غير معتاد أو ضعف أو انقطاع التنفس عند عمل مجهود (علامات قد تدل على مرض يُصيب مستوى خلايا الدم الحمراء)، قلق، تنميل أو خدر ونقص حساسية الجلد، زيادة حساسية الجلد للشمس، ضوضاء (مثل صفير) في الأذنين، حمى، وتناقص الوزن.</p><p>&nbsp;</p><p><strong>بعض الآثار الجانبية نادرة <em>(تُصيب على الأرجح 1 إلى 10 من كل 10000 مريض)</em>:</strong></p><p>اصفرار العينين أو الجلد (مشاكل في الكبد) وخلل في نتائج اختبارات وظائف الكبد.</p><p>&nbsp;</p><p><strong>بعض الآثار الجانبية نادرة جداً <em>(تُصيب على الأرجح أقل من 1 من كل 10000 مريض)</em>:</strong></p><p>نقص في أنواع معيَّنة من خلايا الدم، مرض الذئبة (أحد أمراض المناعة الذاتية)، تفاعلات جلدية خطيرة، تفاعلات أرجية (حساسية)، طفح جلدي شبيه بالصدفية (طفح له مظهر فضي اللون)، تفاقم حالات الصدفية، طفح جلدي مصحوب بقشور، وسقوط الشعر.</p><p><strong>&nbsp;</strong></p><p><strong>تم أيضاً الإبلاغ عن الآثار الجانبية التالية:</strong></p><p>تفاعلات حساسية شديدة أو عدوى شديدة، التهاب في الأوعية الدموية، اضطرابات في حاسة الشم تشمل الفقدان الدائم للقدرة على الشم، أو نقص القدرة على الشم، غشاوة في الإبصار، نقص حدة الإبصار، التهاب البنكرياس، طفح جلدي ناتج عن ارتفاع مستوى نوع معيَّن من خلايا الدم البيضاء، نخر عضلي، أعراض شبيهة بالأنفلونزا (مثل التعب، الرعشة، التهاب الحلق، ألم في المفاصل أو العضلات)، ارتفاع أحد إنزيمات العضلات في الدم (كرياتين فوسفوكيناز).</p><p>إذا حدثت لديك إصابة شديدة بأي من هذه الأمور، <strong>أخبر طبيبك</strong>.</p><p>&nbsp;</p><p>إذا لاحظت أي آثار جانبية أخرى غير مذكورة في هذه النشرة، برجاء أن تخبر طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;احفظ أقراصك بعيداً عن الضوء، في عبوتها الأصلية.</li><li>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; لا تستعمل الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة. تاريخ الإنتهاء يُشير إلى آخر يوم يوم من الشهر المذكور.</li><li>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; يُحفَظ في درجة حرارة لا تزيد عن 25 &deg;م.</li><li>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;يُحفظ بعيداً عن متناول ونظر الأطفال.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>الأقراص 250 مجم</strong></p><p><strong>المادة الفعالة</strong> في لاميزيل هي تيربينافين هيدروكلوريد.</p><p><strong>المكونات الأخرى </strong>هي ستيارات ماغنسيوم؛ سيليكا غروانية لامائية؛ هيدروكسي بروبيل ميثيل سيليلوز؛ سيليلوز دقيق التبلور؛ صوديوم كربوكسي ميثيل نشا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            يتوافر لاميزيل في شكل أقراص محزَّزة.
●	أقراص 250 مجم (محزَّزة): يحتوي كل قرص على 250 مجم تيربينافين هل هيئة هيدروكلوريد.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p>www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تم اعتماد هذه النَّشرة من قبل شركة نوفارتس للأدوية في تاريخ 12/2015 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lamisil® Tablets 250mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 281.25mg terbinafine hydrochloride, equivalent to 250mg terbinafine.
For a full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets for oral administration.

LAMISIL Tablets 250mg:
Whitish to yellow tinged white, circular, biconvex tablets, scored on one side and coded LAMISIL 250 on the other.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fungal infections of the skin and nails caused by <em>Trichophyton </em>(eg. <em>T. rubrum</em>, <em>T.mentagrophytes, T. verrucosum, T. violaceum</em>), <em>Microsporum canis </em>and <em>Epidermophyton floccosum</em>.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral Lamisil is indicated in the treatment of ringworm (tinea corporis, tinea cruris and tinea pedis) where oral therapy is considered appropriate due to the site, severity or extent of the infection.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral Lamisil is indicated in the treatment of onychomycosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Adults</u></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 250mg once daily.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The duration of treatment varies according to the indication and the severity of the infection.</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Skin infections</u></em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Likely durations of treatment are as follows:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tinea pedis (interdigital, plantar/moccasin type):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 to 6 weeks</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tinea corporis:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 4 weeks</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tinea cruris:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2 to 4 weeks</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp; <u>Onychomycosis</u></em></p><p>The duration of treatment for most patients is between 6 weeks and 3 months.&nbsp; Treatment periods of less than 3 months can be anticipated in patients with fingernail infection, toenail infection other than of the big toe, or patients of younger age.&nbsp; In the treatment of toenail infections, 3 months is usually sufficient although a few patients may require treatment of 6 months or longer.&nbsp; Poor nail outgrowth during the first weeks of treatment may enable identification of those patients in whom longer therapy is required.</p><p>&nbsp;</p><p>Complete resolution of the signs and symptoms of infection may not occur until several weeks after mycological cure.</p><p>&nbsp;</p><p><strong><u>Additional information on special population</u></strong></p><p>&nbsp;</p><p><em><u>Liver impairment</u></em></p><p>Lamisil tablets are not recommended for patients with chronic or active liver disease (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>The use of Lamisil tablets has not been adequately studied in patients with renal impairment and is therefore not recommended in this population (see section 4.4 Special warnings and precautions for use and section 5.2 Pharmacokinetic properties).</p><p>&nbsp;</p><p><strong><u>Children</u></strong></p><p>A review of safety experience with oral LAMISIL in children, which includes 314 patients involved in the UK LAMISIL Post Marketing Surveillance study, has shown that the adverse event profile in children is similar to that seen in adults. No evidence of any new, unusual or more severe reactions to those seen in the adult population&nbsp; have been noted. However, as data is still limited its use is not recommended.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong><u>Elderly</u></strong></p><p>There is no evidence to suggest that elderly patients (aged 65 years or above) require different dosages or experience side-effects different to those of younger patients.&nbsp; The possibility of impairment of liver or kidney function should be considered in this age group (see Precautions).</p><p>&nbsp;</p><p><strong><u>Method of administration</u></strong></p><p>The scored tablets are taken orally with water. They should preferably be taken at the same time each day and can be taken on an empty stomach or after a meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to Lamisil or to any of the excipients of Lamisil tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Liver Function</u></strong></p><p>Lamisil tablets are not recommended for patients with chronic or active liver disease.&nbsp; Before prescribing Lamisil tablets, a liver function test should be performed and any pre-existing liver disease should be assessed.</p><p>&nbsp;</p><p>Hepatotoxicity may occur in patients with and without pre-existing liver disease therefore periodic monitoring (after 4-6 weeks of treatment) of liver function test is recommended. Lamisil tablets should be immediately discontinued in case of elevation of liver function test.</p><p>Very rare cases of serious liver failure (some with a fatal outcome, or requiring liver transplant) have been reported in patients treated with Lamisil tablets. In the majority of liver failure cases the patients had serious underlying systemic conditions and a causal association with the intake of Lamisil tablets was uncertain (see section 4.8 Undesirable effects).</p><p>&nbsp;</p><p>Patients prescribed Lamisil tablets should be instructed to report immediately any signs or symptoms suggestive of liver dysfunction such as pruritus, unexplained persistent nausea, decreased appetite, anorexia, jaundice, vomiting, fatigue, right upper abdominal pain, dark urine, or pale stools.&nbsp; Patients with these symptoms should discontinue taking oral terbinafine and the patient&rsquo;s liver function should be immediately evaluated.</p><p>&nbsp;</p><p><strong>Dermatological effects</strong></p><p>Serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms) have been very rarely reported in patients taking Lamisil tablets. If progressive skin rash occurs, Lamisil tablets treatment should be discontinued.</p><p>&nbsp;</p><p>Lamisil should be used with caution in patients with pre-existing psoriasis, as very rare cases of exacerbation of psoriasis have been reported.</p><p><strong>&nbsp;</strong></p><p><strong>Haematological effects</strong></p><p>Very rare cases of blood dyscrasias (neutropenia, agranulocytosis, thrombocytopenia, pancytopenia) have been reported in patients treated with Lamisil tablets. Aetiology of any blood dyscrasias that occur in patients treated with Lamisil tablets should be evaluated and consideration should be given for a possible change in medication regimen, including discontinuation of treatment with Lamisil tablets.</p><p>&nbsp;</p><p><strong>Renal function</strong></p><p>In patients with renal impairment (creatinine clearance less than 50&nbsp;mL/min or serum creatinine of more than 300 micro mol/L) the use of Lamisil tablets has not been adequately studied, and therefore, is not recommended (see section 5.2 Pharmacokinetic properties).</p><p>&nbsp;</p><p><strong>Other</strong></p><p>Lamisil should be used with caution in patients with lupus erythematosus as very rare cases of lupus erythematosus have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of other medicinal products on terbinafine</u></p><p>The plasma clearance of terbinafine may be accelerated by drugs which induce metabolism and may be inhibited by drugs which inhibit cytochrome P450. Where co-administration of such agents is necessary, the dosage of Lamisil may need to be adjusted accordingly.</p><p>&nbsp;</p><p>The following medicinal products may increase the effect or plasma concentration of terbinafine:</p><p>&nbsp;</p><p>Cimetidine decreased the clearance of terbinafine by 30%.</p><p>&nbsp;</p><p>Fluconazole increased the Cmax and AUC of terbinafine by 52% and 69% respectively, due to inhibition of both CYP2C9 and CYP3A4 enzymes. Similar increase in exposure may occur when other drugs which inhibit both CYP2C9 and CYP3A4 such as ketoconazole and amiodarone are concomitantly administered with terbinafine.</p><p>&nbsp;</p><p>The following medicinal products may decrease the effect or plasma concentration of terbinafine:</p><p>&nbsp;</p><p>Rifampicin increased the clearance of terbinafine by 100%.</p><p>&nbsp;</p><p><u>Effect of terbinafine on other medicinal products</u></p><p>Terbinafine may increase the effect or plasma concentration of the following medicinal products:</p><p>&nbsp;</p><p>Caffeine &ndash; Terbinafine decreased the clearance of caffeine administered intravenously by 21%.</p><p>&nbsp;</p><p>Compounds predominantly metabolised by CYP2D6 &ndash; In vitro and in vivo studies have shown that terbinafine inhibits the CYP2D6-mediated metabolism.&nbsp; This finding may be of clinical relevance for patients receiving compounds predominantly metabolised by CYP2D6, e.g. certain members of the following drug classes, tricyclic antidepressants (TCA&rsquo;s), &beta;-blockers, selective serotonin reuptake inhibitors (SSRIs), antiarrhythmics (including class 1A, 1B and 1C) and monoamine oxidase inhibitors (MAO-Is) Type B, especially if they also have a narrow therapeutic window (see section 4.4).</p><p>&nbsp;</p><p>Terbinafine decreased the clearance of desipramine by 82%.</p><p>&nbsp;</p><p>In studies in healthy subjects characterized as extensive metabolisers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increased the dextromethorphan/dextrorphan metabolic ratio in urine by 16- to 97-fold on average. Thus, terbinafine may convert extensive CYP2D6 metabolisers (genotype) to poor metaboliser status (phenotype).</p><p>&nbsp;</p><p><u>Information on other drug concomitantly used with Lamisil resulting in no or negligible interactions.&nbsp; </u></p><p>Studies undertaken in vitro and in healthy volunteers suggest that terbinafine shows negligible potential to inhibit or induce the clearance of most drugs that are metabolized via other cytochrome P450 enzymes (e.g. tolbutamine, terfenadine, triazolam, oral contraceptives) with exception of those metabolised through CYP2D6 (see below).</p><p>&nbsp;</p><p>Terbinafine does not interfere with the clearance of antipyrine or digoxin.</p><p>&nbsp;</p><p>There was no effect of terbinafine on the pharmacokinetics of fluconazole. Further there was no clinically relevant interaction between terbinafine and the potential comedications cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline.</p><p>Some cases of menstrual disturbance (breakthrough bleeding and irregular cycle) have been reported in patients taking Lamisil concomitantly with oral contraceptives, although the incidence of these disorders remains within the background incidence of patients taking oral contraceptives alone.</p><p>&nbsp;</p><p>Terbinafine may decrease the effect or plasma concentration of the following medicinal products:</p><p>&nbsp;</p><p>Terbinafine increased the clearance of ciclosporin by 15%.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Rare cases of changes in INR and/or prothrombin time have been reported in patients receiving terbinafine concomitantly with warfarin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Foetal toxicity and fertility studies in animals suggest no adverse effects. Since clinical experience in pregnant women is very limited, terbinafine tablets should not be used during pregnancy unless clinical condition of the woman requires treatment with oral terbinafine and the potential benefits for the mother outweigh any potential risks for the foetus.</p><p>&nbsp;</p><p><u>Lactation</u></p><p>Terbinafine is excreted in breast milk and therefore mothers should not receive Lamisil treatment whilst breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Foetal toxicity and fertility studies in animals suggest no adverse effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Lamisil tablets treatment on the ability to drive and use machines have been performed. Patients who experience dizziness as an undesirable effect should avoid driving vehicles or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Side effects are generally mild to moderate, and transient.&nbsp; The following adverse reactions have been observed in the clinical trials or during post-marketing experience.</p><p>&nbsp;</p><p>Adverse reactions are ranked under headings of frequency, using the following convention:</p><p>Very common (&ge; 1/10); Common (&ge; 1/100, &lt; 1/10); Uncommon (&ge; 1/1,000, &lt;1/100); Rare (&ge; 1/10,000, &lt; 1/1,000); Very rare (&lt; 1/10,000), Not known (frequency cannot be estimated from available data) including isolated reports.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:1160px"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p>&nbsp;</p></td><td style="vertical-align:top; width:1047px"><p>Neutropenia, agranulocytosis, thrombocytopenia.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Anaemia Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1047px"><p>Anaphylactoid reactions (including angioedema), cutaneous and systemic lupus erythematosus.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Anaphylactic reaction, serum sickness-like reaction.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top; width:1047px"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Anxiety and depressive symptoms secondary to taste disturbances</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:1047px"><p>Headache</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:1047px"><p>Taste disturbances, including taste loss, which usually recover within several weeks after discontinuation of the drug. Isolated cases of prolonged taste disturbance have been reported, sometimes leading to a decrease of food intake and significant weight loss.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:1047px"><p>Paraesthesia, hypoaesthesia, dizziness</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Anosmia including permanent anosmia, hyposmia.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1047px"><p>Vertigo</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Hypoacusis, impaired hearing, tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top; width:1047px"><p>Gastrointestinal symptoms (feeling of fullness abdominal distension, dyspepsia, nausea, abdominal pain, diarrhoea).</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:1047px"><p>Cases of serious hepatic dysfunction, including hepatic failure, hepatic enzymes increased, jaundice, cholestasis and hepatitis.&nbsp; If hepatic dysfunction develops, treatment with Lamisil should be discontinued (see also Section 4.4).&nbsp; Very rare cases of serious liver failure have been reported (some with a fatal outcome, or requiring liver transplant).&nbsp; In the majority of liver failure cases the patients had serious underlying systemic conditions and a causal association with the intake of Lamisil was uncertain.&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top; width:1047px"><p>Non-serious forms of skin reactions (rash, urticaria).</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top; width:1047px"><p>Serious skin reactions (e.g. Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p>Photosensitivity (e.g. photodermatosis, photosensitivity allergic reaction and polymorphic light eruption).</p><p>Alopecia</p><p>If progressive skin rash occurs, Lamisil treatment should be discontinued.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Psoriasiform eruptions or exacerbation of psoriasis. Serious skin reactions (e.g. acute generalized exanthematous pustulosis (AGEP)).</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top; width:1047px"><p>Musculoskeletal reactions (arthralgia, myalgia).</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Rhabdomyolysis</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders</strong></p></td><td style="vertical-align:top; width:1047px"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:1047px"><p>Malaise</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Fatigue</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:1047px"><p>Influenza-like illness, pyrexia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top; width:1047px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:1047px"><p>Blood creatine phosphokinase increased</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting adverse reactions after authorisation of the medicinal product is important.&nbsp; It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -- Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A few cases of overdose (up to 5g) have been reported, giving rise to headache, nausea, upper abdominal pain and dizziness. The recommended treatment of overdosage consists of eliminating the drug, primarily by the administration of activated charcoal, and giving symptomatic supportive therapy if needed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- <em>Pharmacotherapeutic group: </em>Oral antifungal agent (ATC code D01B A02)</p><p><em>- Mechanism of action:</em></p><p>Terbinafine is an allylamine which has a broad spectrum of antifungal activity.&nbsp; At low concentrations terbinafine is fungicidal against dermatophytes, moulds and certain dimorphic fungi.&nbsp; The activity versus yeasts is fungicidal or fungistatic depending on the species.</p><p>&nbsp;</p><p>Terbinafine interferes specifically with fungal sterol biosynthesis at an early step.&nbsp; This leads to a deficiency in ergosterol and to an intracellular accumulation of squalene, resulting in fungal cell death.&nbsp; Terbinafine acts by inhibition of squalene epoxidase in the fungal cell membrane.&nbsp; The enzyme squalene epoxidase is not linked to the cytochrome P450 system.</p><p>&nbsp;</p><p>When given orally, the drug concentrates in skin at levels associated with fungicidal activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following oral administration, terbinafine is well absorbed (&gt;70%) and the absolute bioavailability of terbinafine from Lamisil tablets as a result of first-pass metabolism is approximately 50%.&nbsp; A single oral dose of 250mg terbinafine resulted in mean peak plasma concentrations of 1.30mg/ml within 1.5 hours after administration. Plasma concentrations decline in a triphasic manor, with a terminal half-life of 16.5 days. At 28 days, when around 70% steady state levels have been achieved, peak concentrations of terbinafine was on average 25% higher and plasma AUC increased by a factor of 2.3 when compared to single dose administration.&nbsp; From the increase in plasma AUC an effective half-life of ~30 hours can be calculated.&nbsp; The bioavailability of terbinafine is moderately affected by food (increase in the AUC of less than 20%), but not sufficiently to require dose adjustments.</p><p>&nbsp;</p><p>Terbinafine binds strongly to plasma proteins.&nbsp; It rapidly diffuses through the dermis and concentrates in the lipophilic stratum corneum.&nbsp; Terbinafine is also secreted in sebum, thus achieving high concentrations in hair follicles, hair and sebum rich skins.&nbsp; There is also evidence that terbinafine is distributed into the nail plate within the first few weeks of commencing therapy.</p><p>&nbsp;</p><p>Terbinafine is metabolised rapidly and extensively by at least seven CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19.&nbsp; Biotransformation results in metabolites with no antifungal activity, which are excreted predominantly in the urine.</p><p>&nbsp;</p><p>No clinically-relevant age-dependent changes in pharmacokinetics have been observed but the elimination rate may be reduced in patients with renal or hepatic impairment, resulting in higher blood levels of terbinafine.</p><p>&nbsp;</p><p>Single dose pharmacokinetic studies in patients with renal impairment (creatinine clearance &lt;50 ml/min) or with pre-existing liver disease have shown that clearance of Lamisil may be reduced by about 50%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In long-term studies (up to 1 year) in rats and dogs no marked toxic effects were seen in either species up to oral doses of about 100mg/kg a day. At high oral doses, the liver and possibly also the kidneys were identified as potential target organs.</p><p>&nbsp;</p><p>In a two-year oral carcinogenicity study in mice, no neoplastic or other abnormal findings attributable to treatment were made up to doses of 130 (males) and 156 (females) mg/kg a day. In a two-year oral carcinogenicity study in rats, an increased incidence of liver tumours was observed in males at the highest dosage level of 69mg/kg a day. The changes which may be associated with peroxisome proliferation have been shown to be species-specific since they were not seen in the carcinogenicity study in mice, dogs or monkeys.</p><p>&nbsp;</p><p>During high-dose studies in monkeys, refractile irregularities were observed in the retina at the higher doses (non-toxic effect level 50mg/kg). These irregularities were associated with the presence of a terbinafine metabolite in ocular tissue and disappeared after drug discontinuation. They were not associated with histological changes.</p><p>&nbsp;</p><p>A standard battery of <em>in vitro</em> and <em>in vivo</em> genotoxicity tests revealed no evidence of mutagenic or clastogenic potential.</p><p>&nbsp;</p><p>No adverse effects on fertility or other reproduction parameters were observed in studies in rats or rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Magnesium stearate, colloidal anhydrous silica, hydroxy propyl methylcellulose, sodium carboxy methyl starch, microcrystalline cellulose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Protect from light. Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC blister pack containing 14 or 28 tablets.</p><p>Not all pack size may be marketed in your country&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2015 by Novartis Pharmaceutical Company
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>